Wednesday, July 8, 2026

Drug profile · INN

solifenacin succinate

solifenacin succinate (SOLIFENACIN SUCCINATE) is a muscarinic acetylcholine receptor m3 antagonist. Associated with Amneal Pharma Europe Ltd. Route of administration: oral. Current US regulatory status: approved.

FDA: approved
US status approved
Patents linked 9
Pipeline programs 3
News articles 0
Drug details — solifenacin succinate
US status
approved
Class
Route
ORAL
Patents
9
Programs
3
Data quality
0.89

Quick answer

solifenacin succinate (SOLIFENACIN SUCCINATE) is a muscarinic acetylcholine receptor m3 antagonist. Associated with Amneal Pharma Europe Ltd. Route of administration: oral. Current US regulatory status: approved.

Key facts

INN solifenacin succinate
Brand SOLIFENACIN SUCCINATE
Mechanism Muscarinic acetylcholine receptor M3 antagonist
Target Muscarinic acetylcholine receptor M2
Route ORAL
Formulation SUSPENSION

Mechanism of action

Muscarinic acetylcholine receptor M3 antagonist

Primary target: Muscarinic acetylcholine receptor M2

Approval history

Authority Status Date
FDA approved

Pipeline programs

  1. Solifenacin succinate Phase 3 · Astellas Pharma · Neurogenic Detrusor Overactivity
  2. Solifenacin Succinate Unknown · Chinese Academy of · Overactive Bladder
  3. solifenacin Unknown · Chinese Academy of · Urinary Incontinence

Related & competitor drugs

  1. bethanechol chloride Muscarinic acetylcholine receptor M3 agonist
  2. fesoterodine fumarate Muscarinic acetylcholine receptor M2 antagonist
  3. oxybutynin Genito-urinary system and sex hormones (G04)
  4. oxybutynin chloride Muscarinic acetylcholine receptor M3 antagonist
  5. tolterodine tartrate Muscarinic acetylcholine receptor M2 antagonist
  6. darifenacin hydrobromide Genito-urinary system and sex hormones (G04)
  1. KR 20240032847

    CLDN18.2 및 CD3에 결합하는 이중특이 결합제

    Expires Mon Mar 07 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  2. CN 105120840

    Composition of tiacumicin compounds

    Expires Tue Nov 27 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  3. EP 1549658

    VERBINDUNGEN AUF GLUKOSEBASIS MIT AFFINITÜT FÜR P-SELEKTIN

    Expires Tue Jul 01 2025 00:00:00 GMT+0000 (Coordinated Universal Time)

    expired
  4. EP 1527086

    VERBINDUNGEN DIE P-SELECTIN BINDEN

    Expires Tue Apr 29 2025 00:00:00 GMT+0000 (Coordinated Universal Time)

    expired
  5. EP 1423413

    SELEKTIV P-SELECTIN BINDENDE PEPTIDISCHE VERBINDUNGEN

    Expires Tue May 28 2024 00:00:00 GMT+0000 (Coordinated Universal Time)

    expired
  6. EP 1392755

    ZUSAMMENSETZUNGEN ENTHALTEND LIPID-POLYMER KONJUGATE

    Expires Tue Feb 27 2024 00:00:00 GMT+0000 (Coordinated Universal Time)

    expired
  7. IS 5505

    Notkun á blöndu díóls og alfa-hýdroxýsýru til að meðhöndla sjúkdóma sem lýsa sér í ofvexti í hornlagi húðþekju

    Expires Mon May 18 2020 00:00:00 GMT+0000 (Coordinated Universal Time)

    expired
  8. HU P9903958

    INSTANT VESICULAR PRODUCT

    Expires Thu Apr 23 2020 00:00:00 GMT+0000 (Coordinated Universal Time)

    expired
  9. HU P9903308

    GRANULS FOR THE PREPARATION OF FAST-DISINTEGRATING AND FAST-DISSOLVING COMPOSITIONS CONTAINING A HIGH AMOUNT OF DRUG

    Expires Mon Mar 23 2020 00:00:00 GMT+0000 (Coordinated Universal Time)

    expired

Frequently asked questions

What is solifenacin succinate?

solifenacin succinate (SOLIFENACIN SUCCINATE) is a muscarinic acetylcholine receptor m3 antagonist. Associated with Amneal Pharma Europe Ltd. Route of administration: oral. Current US regulatory status: approved.

What is the brand name for solifenacin succinate?

SOLIFENACIN SUCCINATE is a marketed brand name for solifenacin succinate. Check FDA Drugs@FDA for the current US label holder and prescribing information.

What is the US approval status of solifenacin succinate?

solifenacin succinate has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.